ライフサイエンスコーパス: enrolment

1 aining regimens for at least 96 weeks before enrolment.

2 treated with the same treatment allocated at enrolment.

3 to repair a hip fracture, were eligible for enrolment.

4 imary outcome was mortality at 6 months from enrolment.

5 %) had received isoniazid prophylaxis before enrolment.

6 me was treatment failure within 7 days after enrolment.

7 including workforce participation and school enrolment.

8 4, and 20, with follow-up for 44 weeks after enrolment.

9 ir last dose of OPV at least 6 months before enrolment.

10 ing a proton-pump inhibitor or H2 blocker at enrolment.

11 ported a lifetime history of TBI with LOC at enrolment.

12 erminated in December, 2008, because of slow enrolment.

13 ery and discharged on DAPT were eligible for enrolment.

14 ept 29, 2014, 795 patients were screened for enrolment.

15 spite triple drug therapy) were eligible for enrolment.

16 d a life expectancy of less than 6 months at enrolment.

17 ectively recorded at standard intervals from enrolment.

18 ons, such as parenting support and preschool enrolment.

19 prevalence at enrolment and incidence after enrolment.

20 phamide could switch to HSCT 12 months after enrolment.

21 y among women more likely to be HPV naive at enrolment.

22 -1 follow-up data or with HIV-1 infection at enrolment.

23 s from selected households were eligible for enrolment.

24 ere collected at a median of 2441 days after enrolment.

25 (or similar) EEG no more than 7 days before enrolment.

26 d, when practical, again at 25-30 days after enrolment.

27 62) decrease for infants of women anaemic at enrolment.

28 ortance, but which frequently preclude trial enrolment.

29 esting of cervicovaginal lavages obtained at enrolment.

30 e assessed GFR in 48 patients 10 years after enrolment.

31 he two groups had similar characteristics at enrolment.

32 on depending on the duration of gestation at enrolment.

33 any grass pollen AIT at least 5 years before enrolment.

34 to 2 years, and here we present findings at enrolment.

35 cribed insulin for at least 12 months before enrolment.

36 years), 357 (24%) had bacterial vaginosis at enrolment.

37 two vs three or more) during the year before enrolment.

38 rst 90 days and deaths up to 12 months after enrolment.

39 s who were anaemic or malnourished at SUMMIT enrolment.

40 cancer by the study physician at the time of enrolment.

41 content were needed from all patients before enrolment.

42 one child had an HIV test within 4 weeks of enrolment.

43 s were administered in three 0.5 mL doses at enrolment, 1 month, and 6 months.

44 f participants with moderate/high anxiety at enrolment (103/200, 52%), with mean 33.0 (SD 9.3) interv

45 s and sanitation practices, were recorded at enrolment (12th week of gestation).

46 At enrolment, 1575 (53%) men with HIV and 560 (32%) men wit

47 s of eight, stratified by gestational age at enrolment (17-25 weeks vs 26-34 weeks).

48 ecipients was followed up for 12 years after enrolment (1999-2001).

49 2 weeks after enrolment, 26 (3%) of 1021 patients in the CPAP group, a

50 nib as the last BCR inhibitor therapy before enrolment, 43 of whom were enrolled in the main cohort a

51 -daily for 5 days, and we stratified them by enrolment 48 h versus 48-120 h since illness onset.

52 After enrolment, 823 women were randomly assigned to receive F

53 who had received bortezomib treatment before enrolment achieved an overall response.

54 ertiles with time to relapse following study enrolment, adjusting for several confounders.

55 The trial was stopped due to slow enrolment after 933 patients were recruited.

56 of recurrent appendix mass within 1 year of enrolment after successful non-operative treatment of ap

57 tervention or to be waitlisted for programme enrolment after the study period and serve as the contro

58 identical to lamotrigine dose prior to study enrolment); after each 14-day period, patients were cros

59 After enrolment, all patients continued the twice-daily regime

60 Before enrolment, all patients had received 3-18 months of imat

61 re scheduled clinic visits by 18 months post-enrolment (among all participants).

62 s after intervention delivery (2 years after enrolment) among children younger than 5 years.

63 ipant withdrew from the trial 240 days after enrolment and 12 died during follow-up (five in the inte

64 articipants provided nasal wash specimens at enrolment and 2, 4, and 7 days after enrolment and were

65 articipants provided nasal wash specimens at enrolment and 2, 4, and 7 days later, and were visited d

66 At enrolment and 3-monthly, we collected socio-demographic

67 At enrolment and 4 years' follow-up we estimated GFR from t

68 rs, expressed as a percentage change between enrolment and 4 years, was available for 26 of 27 patien

69 decline in both FEV0.5 and FEF25-75 between enrolment and age 3 years.

70 The trial has completed enrolment and all patients are now off study.

71 thymic carcinoma was deemed ineligible after enrolment and did not receive protocol treatment.

72 iagnosed less than 1 year before the date of enrolment and excluded patients with any other malignanc

73 proxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL

74 proxil fumarate for at least 6 months before enrolment and had creatinine clearance of at least 50 mL

75 who had a stroke within the 3 months before enrolment and had mild-to-moderate upper extremity motor

76 umulative incidence to include prevalence at enrolment and incidence after enrolment.

77 terviews were conducted with participants at enrolment and over 3 months to determine how self-tests

78 165 mm Hg and diastolic 85-105 mm Hg at both enrolment and randomisation, and a mean 24 h blood press

79 because their parents withdrew consent after enrolment and randomisation, so 939 infants actually rec

80 Re-enrolment and re-treatment were also well tolerated.

81 Older age at enrolment and symptomatic generalised epilepsy syndrome

82 tcome was treatment failure within 7 days of enrolment and the primary analysis was per protocol.

83 emain on treatment, this trial has completed enrolment and this represents the final analysis.

84 between patients who had angiography before enrolment and those who had not.

85 rticipants who were HCV antibody-positive at enrolment and those with HCV antibody seroconversion dur

86 mens at enrolment and 2, 4, and 7 days after enrolment and were visited daily by a research assistant

87 ad to be clinically free of breast cancer at enrolment and without evidence of recurrent disease at a

88 em were receiving anti-VEGF therapy prior to enrolment) and 26 controls were analysed by flow cytomet

89 y (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day bre

90 s trial was done between Dec 15, 2015 (first enrolment), and May 19, 2016 (final visit of the last en

91 ong those who started ART within 6 months of enrolment); and the proportion who missed two or more sc

92 ) underwent transplantation within 1 year of enrolment, and 5 of 51 patients died.

93 sults, and HIV test results were recorded at enrolment, and each participant gave at least three sput

94 5-40 years of age, 17-34 weeks' gestation at enrolment, and had not previously received any influenza

95 ani grade 2 or 3, disease progression before enrolment, and no previous chemotherapy for sarcoma or p

96 o had given birth to one healthy baby during enrolment, and who expressed their intentions of visitin

97 al blood obtained at the time of the initial enrolment assessment.

98 undergoing allogeneic HSCT were planned for enrolment at 16 transplant centres in the USA.

99 The study was terminated after 22 months of enrolment because buprenorphine was shown to have greate

100 Study enrolment began in January, 1994, and two cohort studies

101 To avoid enrolment bias, we classified patients as standard risk

102 The study is closed to enrolment but continues to follow up and treat patients.

103 This study is closed to enrolment but patients' treatment and follow-up is ongoi

104 The study is closed for enrolment but treatment and follow-up of patients is ong

105 tudy staff and parents of participants after enrolment, but group allocation was masked from laborato

106 The study has completed enrolment, but patients are still in follow-up for overa

107 On days when trial enrolment capacity was reached, patients were enrolled i

108 se subtype (0.12, 0.02-0.95; p=0.04) and the enrolment centre being located in the USA (0.56, 0.39-0.

109 anial haemorrhage less than 12 months before enrolment, clinically significant cardiovascular disease

110 ifornia (Berkeley, CA, USA) and had adequate enrolment co-test results.

111 g of cases to controls was 1:1 but, in 2006, enrolment criteria for cerebral malaria survivors were r

112 trations at the time of recurrence and study enrolment criteria.

113 patients aged 15 years or older with a known enrolment date between 1997 and 2014.

114 eral artery tonometry are being performed at enrolment, defervescence, and follow-up FINDINGS: To dat

115 outcome was treatment failure by day 8 after enrolment, defined as clinical deterioration, developmen

116 outcome was treatment failure by day 8 after enrolment, defined as clinical deterioration, developmen

117 s who started treatment in the 8 weeks after enrolment did not differ significantly between groups (5

118 ort (one patient), or too late for the trial enrolment (five patients).

119 aviours using questionnaires administered at enrolment, follow up, and graduation visits.

120 utions to the key challenges involved in the enrolment, follow-up, and analysis of such a trial.

121 Enrolment followed a two-stage design: to proceed to the

122 Enrolment for RADIANT-4 was completed on Aug 23, 2013, b

123 Trial protocol registration before patient enrolment for randomized controlled trials (RCTs) is a p

124 Here, we report results from phase 2; enrolment for the study began on Feb 16, 2010, and ended

125 Enrolment for the trial ran between December, 2001, and

126 Enrolment for this trial is closed and results of the fi

127 or those who were HPV-16/18 DNA-positive at enrolment (for the HPV-16/18 endpoint), we calculated va

128 dyads (87% of the 1489 dyads in the original enrolment) for assessment when the child was 4 years of

129 Enrolment forced expiratory flows and volumes infant pul

130 secondary care sites in ten countries, with enrolment from Nov 28, 2008, to July 15, 2009.

131 3.5 cm) or anaemic (haemoglobin <110 g/L) at enrolment had a reduction in early infant mortality of 2

132 The 840 mg dose was discontinued after enrolment had begun because comparable activity of the d

133 Patients eligible for enrolment had essential hypertension, were aged 18 years

134 Enrolment has been completed.

135 23 women who were taking oestrogen at study enrolment has developed Alzheimer's disease.

136 At enrolment, HIV-1 infected participants had CD4 counts of

137 o were HPV 16 and HPV 18 seronegative before enrolment (HPV naive), and also in the full cohort of wo

138 Patients aged 35-85 years were eligible for enrolment if they had blood pressure more than 140/90 mm

139 nts aged 18 years or older were eligible for enrolment if they had ST-segment elevation myocardial in

140 Patients were eligible for enrolment if they were aged 18 years or older, diagnosed

141 Patients were eligible for enrolment if they were aged 18 years or older, had a con

142 ex, CD4 cell count, and WHO disease stage at enrolment in care and initiation of antiretroviral thera

143 he benefit to HIV-positive patients of early enrolment in care and initiation of antiretroviral thera

144 wards universal coverage, such as increasing enrolment in government health insurance, a movement tow

145 stematic analysis of data for clinical trial enrolment in Great Britain over 6 years (2005-10), and r

146 to care interventions might decrease time to enrolment in HIV care and antiretroviral treatment and t

147 as all-cause mortality rate at 2 weeks after enrolment in patients for whom data were available after

148 previous injecting drug users at the time of enrolment in the BTS, were offered daily oral tenofovir

149 5928 (76%) women were eligible for enrolment in the extension, and of these, 4550 (77%) wer

150 data from 12 963 children aged 9-14 years at enrolment in the Growing Up Today Study, and their mothe

151 On the basis of our findings, enrolment in the PATCH trial has been extended, with a p

152 h at least 12 months of continuous insurance enrolment in the previous year, 12-month follow-up, and

153 Three years after enrolment in the RCT, mortality dates of all surgical pa

154 included in this study on the basis of their enrolment in these clinical trials and the availability

155 ralia, the USA, and the UK were eligible for enrolment in this double-blind, randomised controlled tr

156 nts aged 18 years or older were eligible for enrolment in this multicentre, open-label, randomised co

157 e from the USA and Ukraine were eligible for enrolment in this phase II, randomised, double-blind, pl

158 Hospital, Kilmarnock, UK, were eligible for enrolment in this phase III, randomised, double-blind, p

159 acute vertebral fractures were eligible for enrolment in this randomised controlled trial at 21 site

160 ne functional independence were eligible for enrolment in this randomised controlled trial at two uni

161 lipidaemia or hypertension were eligible for enrolment in this randomised, double-blind, placebo-cont

162 otected sexual intercourse were eligible for enrolment in this randomised, multicentre, non-inferiori

163 independent core laboratory at completion of enrolment, in all randomly allocated participants who ha

164 To estimate post-enrolment incidence, we used Weibull survival models.

165 rogramme in 2002, average CD4 cell counts at enrolment increased (from 101 cells/muL [IQR 44-156] in

166 Enrolment into ARIEL2 Part 1 is complete, although an ex

167 stroke and patients who may be targeted for enrolment into clinical trials comparing anticoagulation

168 Registry Integrating Datasets, Genomics, and Enrolment into Clinical Trials) registry in Dundee, UK.

169 o restrictions on current renal function for enrolment into iPrEx OLE, in which participants were giv

170 after 12 weeks in order to be considered for enrolment into the extension study.

171 Enrolment into the lowest dose group was stopped early a

172 stage of this Simon two-stage design trial; enrolment into the second stage is continuing.

173 Enrolment into this cohort is closed, but patients are s

174 tatic urothelial carcinoma were screened for enrolment into this study; 249 patients were eligible an

175 iochemical failure who would be suitable for enrolment into trials of treatment intensification.

176 ta for 22 188 mothers from the five cohorts, enrolment into which took place at various times between

177 Study enrolment is closed and overall survival follow-up is in

178 Enrolment is complete and this report represents the fin

179 Patient enrolment is complete, although treatment and collection

180 Patient enrolment is complete, but follow-up is ongoing.

181 lowing: stroke or death within 30 days after enrolment, ischaemic stroke in the territory of the qual

182 In CLTS villages, younger children at enrolment (<2 years) showed greater improvements in heig

183 entary young men were screened (n = 100) for enrolment (n = 24) based upon having 1 of 4 haplotype pa

184 ted on Feb 16, 2014, before reaching planned enrolment (n=150) because of poor efficacy.

185 Enrolment numbers were lower than planned because of man

186 Enrolment occurred from December, 2005, to June, 2009, w

187 population was 46% female with median age at enrolment of 11.1 years.

188 r each group, the second stage of the trial (enrolment of 20 additional patients) could proceed if at

189 The trial was terminated early after enrolment of 3232 patients due to severe allergic reacti

190 Ten adults were treated before enrolment of children started.

191 ncouraged to work with the FDA to expand the enrolment of elderly patients in clinical trials of tran

192 tions into universities and greatly expanded enrolment of health professionals.

193 of results by regulatory agencies, including enrolment of heterogeneous groups of patients and varyin

194 6 weeks after enrolment of index patients, 392 (67%) of 586 partners h

195 rugs are being actively investigated and the enrolment of patients in clinical trials is encouraged.

196 The enrolment of patients into these studies is critical to

197 ablish baseline symptom levels nor limit the enrolment of patients to those with the most severe symp

198 ts with at least 20 patients and 3 months of enrolment of patients were included in this analysis.

199 Enrolment of the paired arm was halted in February 2008

200 We began enrolment on April 24, 2013, and completed follow-up on

201 In Kenya and Nigeria, we started enrolment on April 4, 2011, and we enrolled the necessar

202 In DR Congo, we started enrolment on Sept 17, 2012, and continued until June 28,

203 faecal sample to identify enteropathogens at enrolment; one follow-up home visit was made about 60 da

204 in treated and untreated X(T), 2 years from enrolment (or, where applicable, 6 months after surgery)

205 nd satisfactory decision about their child's enrolment, or non-participation, in cancer clinical tria

206 y of the qualifying artery beyond 30 days of enrolment, or stroke or death within 30 days after a rev

207 urs worked), cognition, literacy, and school enrolment owing to very low certainty evidence.

208 At any instant during the year after enrolment, patients in the intervention group were less

209 After enrolment, patients received 6 weeks of medication optim

210 een 30 March 2015 and 30 June 2017, with the enrolment period ending on 31 July 2016.

211 The original enrolment period included children born in the study are

212 and assessed them for cognitive function at enrolment (pre-treatment), and again after 8 weeks of tr

213 On univariate analysis increasing age at enrolment, previous squamous cell carcinoma, having the

214 ree survival at 12 months and 24 months from enrolment, progression-free survival, and overall surviv

215 ing from 6.4 to 17.6, depending on preschool enrolment rate and discount rate.

216 recruit patients at the prespecified minimum enrolment rate because of increased use of statins.

217 Increasing enrolment rates could place schools in a crucial positio

218 in test positive (ie, >/=5 mm induration) at enrolment received a substantial benefit from continued

219 Early enrolment reduced behavioural problems for all children

220 ipants who reported being sexually active at enrolment reported abstinence at their follow-up visit (

221 ticipants who reported not using a condom at enrolment reported using condoms at their first follow-u

222 An enrolment SB-FENO concentration >/= 30 p.p.b. predicted

223 on the biopsy visit immediately after their enrolment screening visit to the total enrolled women.

224 ntions and study populations, countries, and enrolment sites.

225 Enrolment started on July 3, 2007, and the last patient

226 children younger than 5 years, regardless of enrolment status.

227 were screened; because of slow recruitment, enrolment stopped with 136 of a planned 345 participants

228 ocated with a computerised randomisation and enrolment system, which masked both participants and car

229 Ocular complications were more frequent at enrolment than at discharge (142 [18%] vs 61 [8%] patien

230 ticipants who started ART within 6 months of enrolment, the proportion who died or had a viral load o

231 At enrolment, the reactive hyperaemic index, a marker of en

232 At enrolment, the two treatment groups were similar in STD

233 The study is closed to enrolment; this report focuses on the cohort with small-

234 nts were masked to treatment assignment from enrolment through week 41 (time of the last injection).

235 rhoea were matched by location of residence, enrolment time (within 2 weeks of the case), and age (1-

236 erm economic effects of increasing preschool enrolment to 25% or 50% in every low-income and middle-i

237 allocation made home visits every week from enrolment to 6 months after delivery.

238 lements, to be taken daily, every month from enrolment to 90 days post partum.

239 Participants were interviewed 6 months after enrolment to ascertain whether they sought HIV care, ver

240 ed to attend a follow-up visit 1 month after enrolment to assess social harms and sexual behaviour.

241 m decrease in haemoglobin concentration from enrolment to day 28 of follow-up in the primaquine treat

242 ding did not vary substantially by time from enrolment to diagnosis, and did not change after adjustm

243 Enrolment to expanded cohorts of those subtypes is ongoi

244 en randomly assigned to treatment-restricted enrolment to patients with tumours wild-type at codons 1

245 (1:1) by a computer-generated assignment at enrolment to receive a programme of structured, task-ori

246 Infants were randomly assigned (1:1) at enrolment to receive oral 10 mg/kg azithromycin or place

247 owed up patients at 6 months and 1 year from enrolment to record symptoms, medications, and outcomes.

248 Trained clinicians assessed patients at enrolment to the cohort, recording clinical symptoms and

249 The outcome of the study was time from enrolment to the next relapse.

250 pairwise randomisation according to order of enrolment) to receive either stimulation on-first or sti

251 Individuals were observed from study enrolment until heart failure development or end of stud

252 vital capacity >10% at 12 months after study enrolment) using a repeated measures model.

253 s (95% CI 8.8-10.7) and median survival from enrolment was 1.8 years (0.9-2.7).

254 Mean GFR at enrolment was 72.4 mL/min per 1.73 m(2) (SD 24.1) in the

255 hic progression in the 6-month period before enrolment was a requirement for inclusion.

256 Enrolment was age-stratified, with about 45% of particip

257 Dietary intake during the week before enrolment was assessed with the validated Block Kids Foo

258 p.b. and tidal-FENO >/= 7 p.p.b. measured at enrolment was associated with a decline in both FEV0.5 a

259 History of TBI with LOC reported at study enrolment was associated with increased risk for TBI wit

260 Prevalence at enrolment was defined as the ratio of women diagnosed wi

261 as 6.7 months (IQR 3.1-10.2), at which point enrolment was not complete.

262 Treatment failure within 7 days of enrolment was reported in 90 (12%) infants who received

263 2015, 86 patients were randomly assigned but enrolment was stopped because of funding reasons.

264 were more common than anticipated, and trial enrolment was stopped early.

265 Enrolment was stopped on Feb 2, 2011, after a recommenda

266 bility of survival to day 14 of </=0.55, and enrolment was stopped.

267 were not told explicitly that the purpose of enrolment was to study the effect of a trial interventio

268 Enrolment was voluntarily halted on Feb 16, 2014, before

269 ry of exacerbations in the year before study enrolment, we identified several novel biomarkers associ

270 After completion of enrolment, we implemented an mOPV2 vaccination campaign

271 prevalences of HIV at screening and HSV-2 at enrolment were 16% and 67%, respectively.

272 Key inclusion criteria for enrolment were Eastern Cooperative Oncology Group perfor

273 1086 TESAOD participants aged 21-70 years at enrolment were eligible for inclusion.

274 those with organic disease identified after enrolment were excluded from the modified intention-to-t

275 lable prospective relapse data subsequent to enrolment were included in this project.

276 prison during the 3 months before open-label enrolment were more likely to return for at least one op

277 Inclusion criteria for enrolment were: age 18 years or older, weight at least 5

278 , and Gender Parity Index for primary school enrolment) were also examined.

279 had fallen at least once in the year before enrolment, were able to walk 18 m without an aid, had no

280 low up was 197 days (IQR 187-209 days) after enrolment, which corresponded to 255 days (228-287) afte

281 e-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive

282 We completed enrolment with 30 patients (24 of whom had not been prev

283 nts were assigned to each cohort in order of enrolment, with the first three patients being assigned

284 2.09, adjusted for sex, age at baseline, and enrolment year).

285 th HBsAg status, adjusting for sex, age, and enrolment year.